IL23A and cancer: Table 2 summarizes similarities and differences of both cytokines with regard to immune responses and diseases. Effective targeting of IL-12 and IL-23 pathways in animal models and clinical trials broadened clinical indications of IL-12/IL-23 effectors in immune-mediated diseases and cancer [42].